• Mentari Therapeutics to merge with InMed Pharmaceuticals, with the combined company operating as Mentari and moving to a new Nasdaq ticker.
• A $200 million private placement is expected to close immediately before the merger, alongside a previously announced $290 million private placement.
• Financings expected to extend cash runway into 2029, supporting Phase 2a readouts for two PACAP-targeted lead programs, including MT-002.
• Post-merger, fully converted and exercised shares outstanding estimated at 601,195,812.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH09875) on July 22, 2026, and is solely responsible for the information contained therein.